Supernus Pharmaceuticals (SUPN) EBITDA Margin Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) EBITDA Margin Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -1,647.00 |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -368.00 |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -17.00 |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -341.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -634.00 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -538.00 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 40.00 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | -3,380.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,380.00 |
| Dec 31, 2025 | -1,415.00 |
| Sep 30, 2025 | -5,460.00 |
| Jun 30, 2025 | -607.00 |
| Mar 31, 2025 | -465.00 |
| Dec 31, 2024 | 1,290.00 |
| Sep 30, 2024 | 1,796.00 |
| Jun 30, 2024 | 2,638.00 |
| Mar 31, 2024 | -556.00 |
| Dec 31, 2023 | -2,113.00 |
| Sep 30, 2023 | 615.00 |
| Jun 30, 2023 | -1,965.00 |
| Mar 31, 2023 | 208.00 |
| Dec 31, 2022 | 1,668.00 |
| Sep 30, 2022 | -2,282.00 |
| Jun 30, 2022 | -1,747.00 |
| Mar 31, 2022 | -880.00 |
| Dec 31, 2021 | -2,612.00 |
| Sep 30, 2021 | -1,423.00 |
| Mar 31, 2021 | -2,045.00 |